Company Adding A Low End System For Sale On Amazon, Walmart & Other Sites, While Second System With A Multi-Patient Monitor Is Perfect For Nursing Homes & Clinics
LOS ANGELES, CA / ACCESSWIRE / December 10, 2019 / Decision Diagnostics Corp. (OTCPINK:DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the GenSure! ("Feather") diabetes test strip for International markets, and its GenChoice! ("Ladybug") test strip now in FDA 510(k) prosecution. The company also markets its PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system and the GenUltimate! 4Pets Test strip and Avantage! meter a proprietary testing product for dogs, cats and horses, and the panacea GenUltimate! TBG ("Dragonfly") diabetes testing system, now awaiting a clinical trial slot in Korea.
DECN announces today that we have decided to import and take control of two products that will round out our product lines in anticipation of our highly anticipated GenUltimate TBG products. The first product, which we named GenAccord! Is a practical FDA cleared lower end product that will be sold on amazon, Walmart and other e-commerce sites. We also anticipate private label and wholesale market to develop. GenAccord! will have a private label equivalent to be sold under the label Advant!
Keith Berman, CEO of DECN commented, "We have been in discussions with both a Korean and a Taiwanese manufacturer, each long standing and viable companies, for the import of a low end product already cleared by the FDA for U.S. sales and approved for CE Mark for European sales. Carrying the DECN brand enhances these products, which are immediately ready for sale in 1Q 2020. No investment in further development is required, which was a prerequisite."
In addition to the lower market end system GenAccord!, the company is also going to add a second system cleared by the FDA for multi-patient use. Multi-patient meters are required where the setting is a nursing home, clinic or health fair. This system will be distributed by a partner.
Mr. Berman continued, "While we have been very successful with our GenUltimate! products, we have lacked the development resources to produce additional niche products. And while we appear to have a big winner and successful potential partner for our TBG products, we lack marketing muscle. Often we have to choose between attendance at trade shows, or buying media advertising. Our most recent products, GenUltimate! TBG and now GenAccord! have succeeded in ‘threading the needle.' On the one hand, GenUltimate! TBG will be joint marketed on a licensing basis where we do not have to invest resources into sales and marketing, and the GenAccord! products are FDA cleared and market ready, and do not require any investment except to create packaging materials."
Mr. Berman concluded, "We have asked our partner to provide a "cocktail napkin" forecast and guaranteed minimum purchases for GenUltimate TBG and we will post most of this information as soon as it is adopted by both companies. As for GenAccord! we are pleased to announce that we anticipate selling an expected thousands of meters each month on Amazon and Walmart at $8.95 per meter ("buy two and keep a spare"), with each customer looking at a 60 day supply of test strips for $49.95. Of course, more about this in the coming days. We will post our forecast.
ABOUT DECISION DIAGNOSTICS CORP
Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN's products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.5 million diabetics worldwide. With new inspired technology diabetic test strips already in the final stages of development, DECN products compete on a worldwide scale with legacy manufacturers currently selling to 71+ percent of a $15+ billion at-home testing market. The company's GenUltimate TBG product is not yet available for sale in the United States or Puerto Rico but is expected to go on sale in select International markets in January 2020.
Forward-Looking Statements:
This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of December 9, 2019 regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.
CONTACT INFORMATION:
Decision Diagnostics Corp.
Keith Berman (805) 446-2973
[email protected]
www.genultimate.com
www.genultimatetbg.com
www.petsureteststrips.com
www.pharmatechdirect.com
SOURCE: Decision Diagnostics Corp.